CALC
NASDAQCalciMedica Inc.
News25/Ratings1
News · 26 weeks240%
2025-10-262026-04-19
Mix1790d
- SEC Filings7(41%)
- Insider6(35%)
- Other3(18%)
- Analyst1(6%)
Latest news
25 items- INSIDERSEC Form 4 filed by Bardin Stephen4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Leheny A. Rachel4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Hebbar Sudarshan4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Stauderman Kenneth A.4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Dunn Michael J.4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Roberts Eric W4 - CalciMedica, Inc. (0001534133) (Issuer)
- SECSEC Form 8-K filed by CalciMedica Inc.8-K - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form EFFECT filed by CalciMedica Inc.EFFECT - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form S-3 filed by CalciMedica Inc.S-3 - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form 10-K filed by CalciMedica Inc.10-K - CalciMedica, Inc. (0001534133) (Filer)
- SECCalciMedica Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Reports 2025 Financial Results and Provides Clinical UpdatesInternal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™Design of pivotal program in acute pancreatitis (AP) expected in 1H 2026JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 LA JOLLA, Calif., March 3, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CalciMedica Inc.SCHEDULE 13G/A - CalciMedica, Inc. (0001534133) (Subject)
- ANALYSTCalciMedica downgraded by H.C. WainwrightH.C. Wainwright downgraded CalciMedica from Buy to Neutral
- SECSEC Form 8-K filed by CalciMedica Inc.8-K - CalciMedica, Inc. (0001534133) (Filer)
- SECCalciMedica Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee RecommendationSafety concern warrants reevaluation of study design, including enrollment criteria Potential future trial with Auxora™ in AKI to be evaluated after data analysis LA JOLLA, Calif., Jan. 28, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF), a population char
- SECSEC Form 10-Q filed by CalciMedica Inc.10-Q - CalciMedica, Inc. (0001534133) (Filer)
- SECCalciMedica Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate UpdatesEnrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026 Positive discussions with FDA on pivotal trial in acute pancreatitis (AP); final trial design expected in 1H 2026 Cash position expected to fund operations into 2H 2026 LA JOLLA, Calif., Nov. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the third quarter ended September 30, 2025
- PRCalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial HypertensionPreclinical data support CRAC channel inhibitor, CM5480, as a potential first-in-class, differentiated therapy for pulmonary arterial hypertension (PAH), both as monotherapy and in combination with existing treatments Cardiac benefit supports the mechanistic rationale for CRAC channel inhibition in acute kidney injury (AKI), being evaluated in the Phase 2 KOURAGE trial with data expected in 1H 2026 LA JOLLA, Calif., Nov. 12, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immun
- PRCalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025Treatment with Auxora significantly reduced IL-17–related inflammation in both kidney and lung, significantly increased glomerular filtration rate (GFR), and decreased renal injury in a rat model of AKI Findings reinforce the mechanistic rationale for Auxora as a potential treatment for severe AKI with respiratory failure, currently being evaluated in the Phase 2 KOURAGE trial LA JOLLA, Calif., Nov. 10, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, toda
- SECSEC Form 8-K filed by CalciMedica Inc.8-K - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form 424B5 filed by CalciMedica Inc.424B5 - CalciMedica, Inc. (0001534133) (Filer)
- INSIDERSEC Form 4 filed by Director Glicklich Alan4 - CalciMedica, Inc. (0001534133) (Issuer)